Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-23T14:30:47.711Z Has data issue: false hasContentIssue false

22 - The economics of cancer-related symptoms: valuing supportive-care interventions

from Section 3 - Clinical Perspectives In Symptom Management and Research

Published online by Cambridge University Press:  05 August 2011

Lesley-Ann Miller
Affiliation:
Emory University School of Medicine
Jane C. Weeks
Affiliation:
Harvard Medical School
Charles S. Cleeland
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Michael J. Fisch
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Adrian J. Dunn
Affiliation:
University of Hawaii, Manoa
Get access

Summary

Health care costs in the United States have been rising for years. Expenditures for health care in the United States grew 6.1% to $2.2 trillion in 2007, when US health care spending was about $7421 per person and accounted for 16.2% of gross domestic product. These rising costs are due in part to the aging population, longer life spans, and greater prevalence of chronic illnesses.

Cancer is one of the most expensive health conditions. More than 1.4 million new cases of invasive cancer and another 1.0 million cases of basal cell and squamous cell skin cancer are projected to be diagnosed in 2008; the overall cost of cancer in 2007, as estimated by the National Institutes of Health, was $219.2 billion, including $89.0 billion for direct medical costs (total of all health expenditures) and $18.2 billion for indirect morbidity costs (cost of lost productivity as a result of illness).

The financial costs of cancer care are substantial, both from a societal perspective and from an individual perspective. Not only is cancer treatment expensive, but the economic burden of diagnosis and supportive care to meet patient needs throughout survival and at the end of life is also considerable. It is important to realize that over the years there has been an improvement in cancer survival, with 66% of patients with cancer surviving for at least five years.

Type
Chapter
Information
Cancer Symptom Science
Measurement, Mechanisms, and Management
, pp. 259 - 267
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Department of Health & Human Services, Centers for Medicare & Medicaid Services. National health expenditure data: Historical. Available from: URL: http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp. Accessed Aug 11, 2009.
American Cancer Society. Cancer facts and figures 2008. Available from: URL: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed Aug 11, 2009.
Elting, LS, Cantor, SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 10(3):189–196, 2002.CrossRefGoogle ScholarPubMed
Sonis, ST, Oster, G, Fuchs, H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19(8):2201–2205, 2001.CrossRefGoogle ScholarPubMed
Elting, LS, Cooksley, C, Chambers, M, Martin, C, Manzullo, E, Rubenstein, E. Outcomes of oral mucositis among cancer patients [abstract]. Multinational Association of Supportive Care in Cancer (MASCC) 14th International Symposium, Boston MA, June 23–26, 2002. Support Care Cancer 10(4):363, 2002. Abstract 34.
Drummond, M, Stoddart, G, Labelle, R, Cushman, R. Health economics: an introduction for clinicians. Ann Intern Med 107(1):88–92, 1987.CrossRefGoogle ScholarPubMed
Elting, LS, Shih, YC. The economic burden of supportive care of cancer patients. Support Care Cancer 12(4):219–226, 2004.CrossRefGoogle ScholarPubMed
Trueman, P, Drummond, M, Hutton, J. Developing guidance for budget impact analysis. Pharmacoeconomics 19(6):609–621, 2001.CrossRefGoogle ScholarPubMed
Taylor, RS, Drummond, MF, Salkeld, G, Sullivan, SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329(7472):972–975, 2004.CrossRefGoogle ScholarPubMed
Arbuckle, RB, Adamus, AT, King, KM. Pharmacoeconomics in oncology. Expert Review of Pharmacoeconomics & Outcomes Research 2(3):251–260, 2002.CrossRefGoogle Scholar
Drummond, MF, Sculpher, MJ, Torrance, GW, O'Brien, BJ, Stoddart, GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. New York: Oxford University Press, 2005.Google Scholar
Russell, LB, Gold, MR, Siegel, JE, Daniels, N, Weinstein, MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276(14):1172–1177, 1996.CrossRefGoogle ScholarPubMed
Gold, MR. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.Google Scholar
Froberg, DG, Kane, RL. Methodology for measuring health-state preferences – II: Scaling methods. J Clin Epidemiol 42(5):459–471, 1989.CrossRefGoogle ScholarPubMed
Gafni, A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res 29(2):207–224, 1994.Google ScholarPubMed
Norum, J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer – is it cost-effective?Acta Oncol 39(1):33–39, 2000.CrossRefGoogle ScholarPubMed
Kurian, AW, Thompson, RN, Gaw, AF, Arai, S, Ortiz, R, Garber, AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 25(6):634–641, 2007.CrossRefGoogle ScholarPubMed
Rothberg, MB, Rose, DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 118(1):68–77, 2005.CrossRefGoogle ScholarPubMed
Hillner, BE, Weeks, JC, Desch, CE, Smith, TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18(1):72–79, 2000.CrossRefGoogle ScholarPubMed
Elkin, EB, Weinstein, MC, Winer, EP, Kuntz, KM, Schnitt, SJ, Weeks, JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22(5):854–863, 2004.CrossRefGoogle ScholarPubMed
Miksad, RA, Schnipper, L, Goldstein, M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?J Clin Oncol 25(28):4506–4507, 2007.CrossRefGoogle ScholarPubMed
Shih, YC, Halpern, MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?CA Cancer J Clin 58(4):231–244, 2008.CrossRefGoogle ScholarPubMed
Bennett, CL, Weeks, JA, Somerfield, MR, Feinglass, J, Smith, TJ. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 17(11):3676–3681, 1999.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×